scholarly journals Radiofrequency Ablation of Hepatocellular Carcinoma: A Literature Review

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Yasunori Minami ◽  
Masatoshi Kudo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Safety Margin ◽  
Surgical Techniques ◽  
Evidence Base ◽  
Current Status ◽  
Probe Design ◽  
Curative Therapy ◽  
Management Of Complications ◽  
Liver Cancers

Radiofrequency ablation (RFA) of liver cancers can be performed safely using percutaneous, laparoscopic, or open surgical techniques, and much of the impetus for the use of RFA has come from cohort series that have provided an evidence base for this technique. Here, we give an overview of the current status of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC), including its physical properties, to assess the characteristics that make this technique applicable in clinical practice. We review the technical development of probe design and summarize current indications and outcomes of reported clinical use. An accurate evaluation of treatment response is very important to secure successful RFA therapy since a sufficient safety margin (at least 0.5 cm) can prevent local tumor recurrences. We also provide a profile of side effects and information on the integration of this technique into the general management of patients with HCC. To minimize complications of RFA, physicians should be familiar with each feature of complication. Appropriate management of complications is essential for successful RFA treatment. Moreover, adjuvant therapy, such as molecular targeted therapies following curative therapy, is expected to further improve survival after RFA.

scholarly journals Radiation therapy for hepatocellular carcinoma: current status and perspectives from our experience

2011 ◽  
pp. 257-264
Author(s):  
Wei Jiang ◽  
Zhao-chong Zeng
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Wide Spectrum ◽  
Distant Metastases ◽  
Current Status ◽  
Radiation Technology ◽  
Tumor Thrombosis ◽  
Liver Cancers ◽  
Advanced Stages ◽  
Promising Treatment

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is accompanied by a poor prognosis. We had reported that radiation therapy has great potential, in a wide spectrum of primary liver cancers, fromlocal advanced stage of the disease to the more advanced stages, with regional nodal metastases, tumor thrombosis, and for palliation of distant metastases. Following the initial observation that HCC is radiosensitive and with the development of radiation technology, radiotherapy has become a feasible and promising treatment modality for HCC, particularly for advanced forms of the disease. Here, we review the substantial amount of available data on radiotherapy for HCC, report on the current status of this application of radiotherapy, and propose future avenues of research.

scholarly journals Radiation therapy for hepatocellular carcinoma: current status and perspectives from our experience

2011 ◽  
Vol 3 (4) ◽  
pp. 257
Author(s):  
Wei Jiang ◽  
Zhao-chong Zeng
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Wide Spectrum ◽  
Distant Metastases ◽  
Current Status ◽  
Radiation Technology ◽  
Tumor Thrombosis ◽  
Liver Cancers ◽  
Advanced Stages ◽  
Promising Treatment

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is accompanied by a poor prognosis. We had reported that radiation therapy has great potential, in a wide spectrum of primary liver cancers, fromlocal advanced stage of the disease to the more advanced stages, with regional nodal metastases, tumor thrombosis, and for palliation of distant metastases. Following the initial observation that HCC is radiosensitive and with the development of radiation technology, radiotherapy has become a feasible and promising treatment modality for HCC, particularly for advanced forms of the disease. Here, we review the substantial amount of available data on radiotherapy for HCC, report on the current status of this application of radiotherapy, and propose future avenues of research.

Hepatocellular Carcinoma Tumor Board: Making Sense of the Technologies

2015 ◽  
pp. e213-e220 ◽  
Author(s):  
Ghassan K. Abou-Alfa ◽  
Jorge Marrero ◽  
John Renz ◽  
Riccardo Lencioni
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
Viral Infections ◽  
Surgical Techniques ◽  
Standard Of Care ◽  
Intermediate Stage ◽  
Tumor Board ◽  
Nonalcoholic Fatty Liver ◽  
Advanced Hcc ◽  
Curative Therapy

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, with a rising global incidence. The vast majority of HCC cases occur in the setting of liver cirrhosis, mainly due to chronic hepatitis C (HCV) or hepatitis B (HBV) viral infections, alcohol consumption, and nonalcoholic fatty liver disease. The new approval of curative therapy with two NS5A inhibitors, ledipasvir and sofosbuvir, for the treatment of HCV will no doubt affect HCC incidence and outcome. No studies have evaluated the use of the new antivirals in patients with HCC. Staging and scoring remain an integral part of the management of patients with advanced HCC. Curative therapies for the treatment of HCC are evolving. Improvements in surgical techniques and risk stratification for orthotopic liver transplantation (OLT) have expanded access and improved the outlook for patients suffering from HCC. Interventional locoregional treatments continue to play a key role in the management of HCC. Transarterial chemoembolization is considered the standard of care for patients with noninvasive multinodular tumors at the intermediate stage. Bland embolization appears to have similar virtues in some studies. Y90 radioembolization represents a promising treatment option for patients unfit or refractory to transarterial chemoembolization. The advent of sorafenib as a standard of care with an improvement in survival sadly remain the only major breakthrough in the treatment of advanced HCC, with mounting negative data from multiple clinical trials. Advances in immunotherapy and customized therapy may hopefully help reverse this tide.

Retrospective study of CT-guided radiofrequency ablation and laparoscopic radiofrequency ablation in the treatment of recurrent small hepatocellular carcinoma against the diaphragmatic dome.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 272-272
Author(s):  
Qin Zheng ◽  
Huaiyin Ding ◽  
Chuandong Zhu ◽  
Lixue Wang ◽  
Yuan Wan
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Postoperative Complications ◽  
Hospital Stay ◽  
Intraoperative Complications ◽  
Safety Margin ◽  
Small Hepatocellular Carcinoma ◽  
Ct Guided ◽  
Significant Difference ◽  
Small Hcc

272 Background: Radiofrequency ablation (RFA) have been used to treat hepatocellular carcinoma (HCC) in the subphrenic area. Very few studies focus on ablation of recurrent small HCC against the diaphragmatic dome. The therapeutic safety, efficacy, and hospital fee have never been compared between CT guided RFA and laparoscopic RFA (L-RFA) either. Methods: CT guided RFA and L-RFA were performed in totally 116 patients with 151 local recurrent HCC lesions abutting the diaphragm. We compared major and minor postoperative complications, hospital stay and fee, overall survival (OS), and local tumor progression (LTP) between two groups for evaluating respective therapeutic efficacy and safety. Moreover, in CT-guided percutaneous RFA group, depending on the locations of recurrent HCC nodules differentiated puncture paths and ablation methods were used, and intraoperative complications were recorded. Results: There is no significant difference in OS and LTP between CT- guided RFA and LRFA.In recorded postoperative complications, the morbidity in CT-guided RFA group is lower than that of L-RFA group. The average safety margin is 8 and 11 mm in CT-guided RFA and LRFA group, respectively. The shoulder and back pain is significantly high in L-RFA group probably due to pneumoperitoneum. Moreover, overall hospital stay and cost is also lower in CT-guided RFA group. Conclusions: Both CT-guided RFA and L-RFA are considered to be an effective approach for recurrent small HCC abutting diaphragm. Particularly, CT-guided RFA is an easy and economic with less complications if suitable puncture paths and ablation methods can be applied.

Sign in / Sign up

Export Citation Format

Share Document